Is tolvaptan indicated for refractory oedema in nephrotic syndrome?
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park, Eun-Sik | - |
dc.contributor.author | Huh, Youn-sung | - |
dc.contributor.author | Kim, Gheun-Ho | - |
dc.date.accessioned | 2022-07-16T00:31:42Z | - |
dc.date.available | 2022-07-16T00:31:42Z | - |
dc.date.created | 2021-05-12 | - |
dc.date.issued | 2015-02 | - |
dc.identifier.issn | 1320-5358 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/157965 | - |
dc.description.abstract | Tolvaptan is useful for correcting dilutional hyponatraemia because of its aquaretic effect. On the other hand, there is a distinct lack of data regarding tolvaptan-induced natriuresis, although previous studies have demonstrated improvement of congestive symptoms and signs in heart failure patients following tolvaptan treatment. Here, we report the case of a 47-year-old man diagnosed with minimal change nephrotic syndrome and whose refractory oedema was immediately controlled by tolvaptan before steroid response was induced. With tolvaptan treatment, patient urine output increased dramatically to approximately 5.5L/day and body weight decreased by 9kg over 5 days. Interestingly, urine sodium concentration, fractional excretion of sodium and urine osmolality all increased in response to tolvaptan administration. However, serum sodium concentration was maintained within the normal range, and mild azotaemia was corrected. Tolvaptan was discontinued after 11 days when heavy proteinuria and generalized oedema had been resolved. We discuss the potential mechanisms by which V-2 receptor antagonists may stimulate natriuresis in the kidney. In conclusion, tolvaptan may be useful as an adjunctive treatment for oedematous disorders. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | WILEY-BLACKWELL | - |
dc.title | Is tolvaptan indicated for refractory oedema in nephrotic syndrome? | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Gheun-Ho | - |
dc.identifier.doi | 10.1111/nep.12348 | - |
dc.identifier.scopusid | 2-s2.0-84921515612 | - |
dc.identifier.wosid | 000348534700009 | - |
dc.identifier.bibliographicCitation | NEPHROLOGY, v.20, no.2, pp.103 - 106 | - |
dc.relation.isPartOf | NEPHROLOGY | - |
dc.citation.title | NEPHROLOGY | - |
dc.citation.volume | 20 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 103 | - |
dc.citation.endPage | 106 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Urology & Nephrology | - |
dc.relation.journalWebOfScienceCategory | Urology & Nephrology | - |
dc.subject.keywordPlus | VASOPRESSIN RECEPTOR ANTAGONIST | - |
dc.subject.keywordPlus | SODIUM-EXCRETION | - |
dc.subject.keywordPlus | HEART-FAILURE | - |
dc.subject.keywordPlus | HYPONATREMIA | - |
dc.subject.keywordPlus | RETENTION | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | WATER | - |
dc.subject.keywordAuthor | collecting duct | - |
dc.subject.keywordAuthor | oedema | - |
dc.subject.keywordAuthor | nephrotic syndrome | - |
dc.subject.keywordAuthor | sodium | - |
dc.subject.keywordAuthor | tolvaptan | - |
dc.identifier.url | https://onlinelibrary.wiley.com/doi/10.1111/nep.12348 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.